Prescribing in Pregnancy and Lactation Monica Tombasco, MS, MSNA, FNP-BC, CRNA Senior Lecturer, Fitzgerald Health Education Associates, LLC North Andover, MA Emergency Medicine Nurse Practitioner Huggins Hospital, Wolfeboro, NH Certified Registered Nurse Anesthetist Catholic Medical Center, Manchester, NH Developed by: Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC, FNAP President, Fitzgerald Health Education Associates, LLC, North Andover, MA Objectives • Having completed the learning activities, the participant will be able to: – Recognize the most appropriate therapeutic choices in health problems for the woman during pregnancy and lactation. Fitzgerald Health Education Associates, LLC 2 Objectives (continued) • Having completed the learning activities, the participant will be able to: (cont.) – Identify potentially problematic medications during pregnancy and lactation that are commonly prescribed for chronic or recurrent health problems. Fitzgerald Health Education Associates, LLC 3 Pregnancy and Lactation • Not diseases – Pregnancy is a symptom- producing condition. – Pregnant and breastfeeding women get sick. 4 Fitzgerald Health Education Associates, LLC References and Resources • Drugs in Pregnancy and Lactation (10 h ed.): A reference for fetal and neonatal risk; Briggs, Freeman, Yaffe (2014) Philadelphia: Lippincott, Williams and Wilkins. • Medication and Mother’s Milk (2016); Thomas Hale, PhD; Amarillo, Tx: Hale Publishing; http://www.medsmilk.com/ • www.safefetus.com/index.htm; Professionally maintained site in the UK Fitzgerald Health Education Associates, LLC 5 Great Resources • www.breastfeedingbasics.org – At Case Western Reserve University • www.perinatology.com/exposures/druglist.h tm – Menu with the basics, opportunity to link with more detailed information • www.OTISpregnancy.org – Organization of Teratology Information Services • Technical and patient information on everything from medications to herbs to hair treatments Fitzgerald Health Education Associates, LLC 6
14
Embed
Preg lactate IL fall 2016rev080516.ppt...• In a recent published systemic review, the risk of persistent pulmonary hypertension of the newborn (PPHN) associated with use of an SSRI
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Prescribing in Pregnancy and LactationMonica Tombasco, MS, MSNA, FNP-BC, CRNA
Senior Lecturer, Fitzgerald Health Education Associates, LLCNorth Andover, MA
Emergency Medicine Nurse Practitioner Huggins Hospital, Wolfeboro, NH
Certified Registered Nurse AnesthetistCatholic Medical Center, Manchester, NH
• Having completed the learning activities, the participant will be able to:– Recognize the most appropriate
therapeutic choices in health problems for the woman during pregnancy and lactation.
Fitzgerald Health Education Associates, LLC 2
Objectives(continued)
• Having completed the learning activities, the participant will be able to: (cont.)– Identify potentially problematic
medications during pregnancy and lactation that are commonly prescribed for chronic or recurrent health problems.
Fitzgerald Health Education Associates, LLC 3
Pregnancy and Lactation
• Not diseases– Pregnancy is a
symptom-producing condition.
– Pregnant and breastfeeding women get sick.
4Fitzgerald Health Education Associates, LLC
References and Resources
• Drugs in Pregnancy and Lactation (10h ed.): A reference for fetal and neonatal risk; Briggs, Freeman, Yaffe (2014) Philadelphia: Lippincott, Williams and Wilkins.
• Medication and Mother’s Milk (2016); Thomas Hale, PhD; Amarillo, Tx: Hale Publishing; http://www.medsmilk.com/
• www.safefetus.com/index.htm; Professionally maintained site in the UK
Fitzgerald Health Education Associates, LLC 5
Great Resources• www.breastfeedingbasics.org
– At Case Western Reserve University
• www.perinatology.com/exposures/druglist.htm– Menu with the basics, opportunity to link with
more detailed information
• www.OTISpregnancy.org– Organization of Teratology Information Services
• Technical and patient information on everything from medications to herbs to hair treatments
Fitzgerald Health Education Associates, LLC 6
Great Resources (continued)
• Use of psychiatric medications during pregnancy and lactation– http://www.guideline.gov/content.aspx?id
=12490, referenced used in this program for comments on psychotropic medications
Fitzgerald Health Education Associates, LLC 7
What is the teratogenic risk?
• For a teratogen to exert its effect, it must be taken at the point in the pregnancy when the affected organ system is developing.
Fitzgerald Health Education Associates, LLC 8
Stages Of Human Development
Orange bars=Highly sensitive periods of development when major defects may be produced;Blue bars=Stages less sensitive to teratogens when minor defects may be induced.
Reproduced with permission from Moore and Persaud. The Developing Human: Clinically Oriented Embryology. 1999.
age of embryo in weeks fetal period (in weeks)
1 2 3 4 5 6 7 8 9 16 20-36 38Period of dividingzygote, implantation& bilaminar embryo Indicates common site of action of teratogenC.N.S.
heart eye eyeearearheart palate
brain
external genitalialimbs
Notsusceptible to
teratogens
major congenital anomaliesprenatal deathfunctional defects &
minor congenital anomalies
ear
external genitalia
teeth
lower limbs
eyes
upper limbs
heart
palate
Central nervous system
full term
teeth
Teratogenic Effect
• Teratogenic effect in lower species may not be seen in higher species. – Example‒ Corticosteroids– Example‒ Ciprofloxacin
• Teratogenic effect in higher species may not be seen in lower species. – Example‒ Thalidomide
Fitzgerald Health Education Associates, LLC 10
Thalidomide exposure en uteroThroughout the world, about 10,000
cases of infants with phocomelia due to thalidomide; only 50% survived.
Available in many European countries in the 1960s, used for morning sickness.
Fitzgerald Health Education Associates, LLC 11
Drug Properties in Pregnancy and Lactation
• Higher MW=More difficult passage– Greater than 1000 d‒ Virtually no passage
• Insulin, UF heparin, LMWH
• 500‒1000 d‒ Difficult• 250‒500 d‒ Easily passed
– The bulk of clinically useful drugs– The lower, the easier
• Alcohol, nicotine, cocaine<100
Fitzgerald Health Education Associates, LLC 12
Drug Properties in Pregnancy and Lactation
(continued)
• Lipophilic easier than hydrophilic– Mammary alveolar
tissue– Placenta– Blood-brain barrier
• Drugs that are potentially sedating or exciting
13Fitzgerald Health Education Associates, LLC
What about this FDA Pregnancy Risk Categories, A, B, C, D, X?
• “FDA has decided to eliminate the pregnancy categories because they are often viewed as confusing and overly simplistic and don’t effectively communicate the risk a drug may have during pregnancy and lactation and in females and males of reproductive potential.”
• The nursing mothers subsection– Was renamed, the lactation
subsection, and provides information about using the drug while breastfeeding, such as the amount of drug in breast milk and potential effects on the breastfed infant
Fitzgerald Health Education Associates, LLC 19
Females and Males of Reproductive Potential
• New to the labeling– Includes information, when necessary
• Need for pregnancy testing, contraception recommendations, and information about infertility as this relates to the use of the drug
Fitzgerald Health Education Associates, LLC 20
When does thePLLR go into effect?
• Prescription drugs, biologic products– Submitted after June 30, 2015, will use
the new format immediately, while labeling for prescription drugs approved on or after June 30, 2001, will be phased in gradually.
Fitzgerald Health Education Associates, LLC 21
Does the FDA recommendations affect all drugs?
• For labeling of products approved prior to June 30, 2001, manufacturers are required to remove the pregnancy category within 3 years of the effective date of the final rule
Fitzgerald Health Education Associates, LLC 22
Does the FDA recommendationsaffect all drugs?
• OTCs– Labeling for over-
the-counter (OTC) medicines will not change.
Fitzgerald Health Education Associates, LLC 23
Example of New Labeling: https://www.byetta.com/home/search?term=pregnancy
• Pregnant and nursing women:– Based on animal data, BYETTA may cause
fetal harm and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. To report drug exposure during pregnancy call 1-800-633-9081. When administered to a nursing woman, a decision should be made whether to discontinue nursing or discontinue BYETTA.
Fitzgerald Health Education Associates, LLC 24
FDA Pregnancy Risk Categories
• Assigned to all drugs– New drug=Animal study and perhaps
small number of inadvertent exposures during clinical trials
• Based on risk of drug exposure to human fetus– Ranked A, B, C, D, X
– Source: Briggs, Freeman & Jaffe, 2011
Fitzgerald Health Education Associates, LLC 25
Category A
• Well-controlled human study fails to demonstrate fetal risk in 1st trimester
• No evidence of risk in 2d, 3d trimesters• Risk to fetus appears remote
– <1% of all medications• Needed for health• Produced by the body
Fitzgerald Health Education Associates, LLC 26
Category A (continued)
• Vitamins in recommended doses– Vitamin A caution
• Risk factor X in doses>8000 units• One Airborne®=Vitamin A 5000 units
• Levothyroxine (Synthroid®) – A bioidentical hormone
• In urgent care with “unexpected” pregnancy dx, what should you advise?
Fitzgerald Health Education Associates, LLC 27
Timing and Magnitude of Increases in Levothyroxine Requirements During Pregnancy in Women with
HypothyroidismAlexander, E. et al. (2004)
NEJM, Volume 351:241‒249. Vol. 3. July 15, 2004
• “An increase in the levothyroxine dose was necessary during 17 of 20 pregnancies. The mean levothyroxine requirement increased 47 percent during the first half of pregnancy (median onset of increase, eight weeks of gestation) and plateaued by week 16. This increased dose was required until delivery.”
Fitzgerald Health Education Associates, LLC 28
Timing and Magnitude of Increases in Levothyroxine Requirements During Pregnancy in Women with
Hypothyroidism (continued) Alexander, E. et al. (2004)
NEJM, Volume 351:241‒249. Vol. 3. July 15, 2004
• Conclusions:– “Levothyroxine requirements increase as early as
the fifth week of gestation. Given the importance of maternal euthyroidism for normal fetal cognitive development, we propose that women with hypothyroidism increase their levothyroxine dose by approximately 30 percent as soon as pregnancy is confirmed.”
Fitzgerald Health Education Associates, LLC 29
When advising a pregnant woman with hypothyroidism…
• On taking her levothyroxine dose, which of the following is the best approach?A. Take with water on an empty stomach. B. Take with food to minimize GI upset. C. Take with her prenatal vitamin to enhance adherence.
Fitzgerald Health Education Associates, LLC 30
When advising a pregnant woman with hypothyroidism…
• On taking her levothyroxine dose, which of the following is the best approach?A. Take with water on an empty stomach. B. Take with food to minimize GI upset. C. Take with her prenatal vitamin to enhance adherence.
Fitzgerald Health Education Associates, LLC 31
Category BB=Best because nothing in A
• Animal studies have not demonstrated fetal risk but no controlled study in humans‒ Or‒
• Animal studies have show adverse effect but not demonstrated in human study
• Many drugs used to treat serious mental and physical health problems– Most SSRIs, atypical antidepressants
Fitzgerald Health Education Associates, LLC 37
Emerging Treatment of Choice in Bipolar Disorder in Pregnancy
• “Lamotrigine (category C) is a potential maintenance therapy option for pregnant women with bipolar disorder because of its protective effects against bipolar depression, general tolerability, and a growing reproductive safety profile relative to alternative mood stabilizers.”
– Teratogenic concern generally less that most common neonatal abstinence findings of restlessness, feeding problems, irritability, and hypothermia
– Usually evident by day 3 of life– Supportive care
Fitzgerald Health Education Associates, LLC 39
True or false?
• In a recent published systemic review, the risk of persistent pulmonary hypertension of the newborn (PPHN) associated with use of an SSRI during pregnancy is estimated to be less than 1%.
• Positive evidence of human fetal risk• Benefit from use in pregnancy might
be acceptable despite the risk – Is the condition potentially life-
threatening disease vs. life-altering?
Fitzgerald Health Education Associates, LLC 41
Category D(continued)
• ACEI (-pril suffix) – 2d, 3d trimester
• ARB (-sartan) – 2d, 3d trimester
• Risk of fetal hypotension, IUFD, renal atrophy
• The tetracyclines– Doxycycline=D
• Carbamazepine– Tegretol®
– Benefit might outweigh risk in seizure disorder
• Lithium– 1:400‒1:4000 risk of
Ebstein anomaly with tricuspid valve and other cardiac problems
Fitzgerald Health Education Associates, LLC 42
After years of use…• “The U.S. Food and Drug Administration
(FDA) is advising health care professionals and women that the anti-seizure medication valproate sodium and related products, valproic acid and divalproex sodium, are contraindicated and should not be taken by pregnant women for the prevention of migraine headaches.
• Based on information from a recent study, there is evidence that these medications can cause decreased IQ scores in children whose mothers took them while pregnant.”
• L2‒ Safer (cont.)– Limited number of women studied
without risk• Prednisone• SSRIs
Fitzgerald Health Education Associates, LLC 58
Which SSRI During Lactation?
• “Results of the pooled analyses indicated that breastfed infants exposed to paroxetine and sertraline were unlikely to develop detectable serum drug levels.
• Infants exposed to fluoxetine through breast milk were more likely to develop elevated levels of the drug especially if the mothers started the treatment during pregnancy (due to prenatal loading).
• The data on citalopram were limited compared the other SSRIs, but suggested that some infants developed quantifiable serum levels of the drug which may be associated with adverse effects.”
(diphenhydramine {Benadryl®}, et al.) • Doxycycline
Fitzgerald Health Education Associates, LLC 63
Hale’s Lactation Risk Category (continued)
• L4‒ Hazardous– Positive evidence of risk but may be used
if maternal life-threatening situation• Lithium• Ergot preparations• HD daily corticosteroids
Fitzgerald Health Education Associates, LLC 64
Hale’s Lactation Risk Category (continued)
• L5‒ Contraindicated– Significant and
documented risk • Radioactive isotopes• Cocaine
Fitzgerald Health Education Associates, LLC 65
Immunizations DuringPregnancy and Lactation
Reference: http://www.cdc.gov/vaccines/pub
s/preg-guide.htm#glines
Immunizations During Pregnancy: Priority Vaccines
• Inactivated influenza – Women in 2d, 3d trimesters at increased
risk for hospitalization from influenza– Routine influenza vaccination
recommended for all women who are or will be pregnant (in any trimester) during influenza season.
Fitzgerald Health Education Associates, LLC 67
Additional Benefits from Influenza Vaccine
• Reduced risk of preterm birth and SGA in immunized moms– Limited to babies born during flu season
• Infants born to mothers who received flu vaccine while pregnant ~50% less likely to be hospitalized for flu than infants born to mothers who did not receive vaccine
• Tdap dose during each pregnancy irrespective of prior Tdap history
• To maximize the maternal antibody response and passive antibody transfer to the infant, optimal timing for Tdap administration is between 27 and 36 weeks of gestation although Tdap can be given at any time during pregnancy.
Fitzgerald Health Education Associates, LLC 69
All household members and caregivers of the newborn should receive the annual influenza and
updated Tdap vaccine. If mom did not receive these
vaccines during pregnancy, she should be immunized postpartum
whether breastfeeding or not.
Conclusion
• Pregnant and lactating women can and do get sick.
• By choosing the best pharmacologic intervention, you can work with her to have the healthiest mom and baby.
• Images/Illustrations: Unless otherwise noted, all images/illustrations are from open sources, such as the CDC or Wikipedia or property of FHEA or author.
• All websites listed active at the time of publication.
Fitzgerald Health Education Associates, LLC 73
Copyright Notice
Copyright by Fitzgerald Health Education Associates, LLCAll rights reserved. No part of this publication may be reproduced or transmitted
in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without permission
from Fitzgerald Health Education Associates, LLC
Requests for permission to make copies of any part of the work should be mailed to:
Fitzgerald Health Education Associates, LLC85 Flagship Drive
North Andover, MA 01845-6184
Statement of Liability
• The information in this program has been thoroughly researched and checked for accuracy. However, clinical practice and techniques are a dynamic process and new information becomes available daily. Prudent practice dictates that the clinician consult further sources prior to applying information obtained from this program, whether in printed, visual or verbal form.
• Fitzgerald Health Education Associates, LLC disclaims any liability, loss, injury or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents of this presentation.
Fitzgerald Health Education Associates, LLC
85 Flagship Drive
North Andover, MA 01845-6154978.794.8366 Fax-978.794.2455